SystImmune is the lead sponsor of 5 current clinical trials in our USA register. 4 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are BL-M05D1, BL-M07D1 and BL-M14D1. The most-studied condition is Endometrial Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 · Endometrial Cancer, Cervical Cancer, Ovarian Cancer
Drug: BL-M07D1 |
Phase 1 | Recruiting | 2024-02 | USA |
|
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
Drugs: Carboplatin, Etoposide |
Phase 3 | Recruiting | 2026-08 | USA |
|
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer
Drug: Iza-bren |
Phase 1 | Recruiting | 2023-08 | USA |
|
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer
Drug: BL-M14D1 |
Phase 1 | Recruiting | 2025-04 | USA |
|
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Drug: BL-M05D1 |
Phase 1 | Active, closed | 2025-07 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 4 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Xencor | 2 |
| Tata Memorial Hospital | 2 |
| Karyopharm Therapeutics | 1 |
| Context Therapeutics | 1 |
| Power Life Sciences | 1 |
| Aadi Bioscience | 1 |
| Regor Pharmaceuticals | 1 |
| Tarapeutics Science | 1 |
Sponsors with the most current trials registered for this condition.
SystImmune is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 6 drugs and biologicals as interventions. The most frequent are BL-M05D1 (1), BL-M07D1 (1), BL-M14D1 (1), Carboplatin (1) and Etoposide (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.